Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 69

Results For "India"

3231 News Found

Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage
News | September 01, 2021

Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage

PPH is associated with almost 20 per cent of maternal mortality in India


Pharma tops India’s exports from SEZs
News | September 01, 2021

Pharma tops India’s exports from SEZs

As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational


Granules India receives approval from Health Canada for arthritis drug
News | August 30, 2021

Granules India receives approval from Health Canada for arthritis drug

Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol


Indian National Institute validates Livinguard’s face mask
Drug Approval | August 28, 2021

Indian National Institute validates Livinguard’s face mask

Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).


Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
News | August 26, 2021

Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra

Domestic business was up 41.9% YoY and 27.7% QoQ


13 hospitals across India complete first cycle of PRIME programme
Healthcare | August 24, 2021

13 hospitals across India complete first cycle of PRIME programme

BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)


DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
Biotech | August 24, 2021

DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial

CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study


Ind-Ra predicts growth in US sales for Indian pharma from H2FY22
News | August 18, 2021

Ind-Ra predicts growth in US sales for Indian pharma from H2FY22

Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume


India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad
interviews | August 17, 2021

India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad

India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers


Indian pharma’s vaccine opportunity at US $ 10-11 billion
Biotech | August 17, 2021

Indian pharma’s vaccine opportunity at US $ 10-11 billion

Domestic market and developing countries will need doses of Indian vaccines